Stockscreener 앱 받기
24.70
2.56%
-0.65
시간 외 거래:
24.78
0.08
+0.32%
Moderna Inc 주식(MRNA)의 최신 뉴스
US health agency fires official who opposed mRNA Covid shots - MarketScreener
New COVID vaccine says it’s for the ‘senior class’ — does it reduce side effects? - San Francisco Chronicle
AlphaQuest LLC Increases Position in Moderna, Inc. $MRNA - MarketBeat
Ethic Inc. Purchases 10,325 Shares of Moderna, Inc. $MRNA - MarketBeat
How Moderna Inc. stock trades before earningsWatch List & Community Verified Swing Trade Signals - newser.com
Will Moderna Inc. stock see insider buyingJuly 2025 Breakouts & Verified Momentum Watchlists - Fundação Cultural do Pará
Why Moderna Inc. stock is a value investor pick2025 Retail Activity & Stock Portfolio Risk Management - Fundação Cultural do Pará
Vertex and Moderna’s VX-522 Study: A Potential Breakthrough in Cystic Fibrosis Treatment - TipRanks
Moderna Says Vax Efficacy Math Doesn't Show Investor Fraud - Law360
What’s next for Moderna Inc. stock priceJuly 2025 Institutional & High Conviction Buy Zone Picks - newser.com
Best data tools to analyze Moderna Inc. stockDollar Strength & Growth Oriented Trade Recommendations - newser.com
Using economic indicators to assess Moderna Inc. potentialTrade Ideas & Real-Time Price Movement Reports - newser.com
Is Moderna Inc. meeting your algorithmic filter criteriaJuly 2025 Closing Moves & Real-Time Buy Zone Alerts - newser.com
D.A. Davidson & CO. Purchases 62,778 Shares of Moderna, Inc. $MRNA - MarketBeat
Why Moderna Inc. stock is favored by top institutionsJuly 2025 Summary & Comprehensive Market Scan Reports - newser.com
Is Moderna Inc. stock in correction or buying zonePortfolio Return Summary & Long-Term Capital Growth Ideas - newser.com
Analysts Set Expectations for Moderna FY2026 Earnings - MarketBeat
FY2026 EPS Estimates for Moderna Lowered by Analyst - MarketBeat
Equities Analysts Issue Forecasts for Moderna Q3 Earnings - MarketBeat
Moderna (NASDAQ:MRNA) Receives Sell (E+) Rating from Weiss Ratings - MarketBeat
Is it too late to sell Moderna Inc.IPO Watch & Accurate Entry and Exit Point Alerts - newser.com
Moderna scraps mRNA vaccine in congenital CMV on trial failure - Medical Dialogues
Moderna to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025 - The Daily News Journal
VIRGINIA RETIREMENT SYSTEMS ET Al Makes New Investment in Moderna, Inc. $MRNA - MarketBeat
How moving averages guide Moderna Inc. trading2025 Trading Volume Trends & Accurate Entry/Exit Alerts - newser.com
Moderna to Host Investor Event – Analyst Day - Shelby Star
Moderna Named a Top Employer by Science for Eleventh Consecutive Year - Bluffton Today
Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism - Pueblo Chieftain
Moderna (MRNA) Outperforms Broader Market: What You Need to Know - Yahoo Finance
JPMorgan Chase & Co. Cuts Moderna (NASDAQ:MRNA) Price Target to $25.00 - MarketBeat
Moderna (NASDAQ:MRNA) Shares Gap Down Following Analyst Downgrade - MarketBeat
Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans - The Daily Jeffersonian
UBS Maintains Moderna (MRNA) Buy Recommendation - Nasdaq
Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint - The Holland Sentinel
How Investors May Respond To Moderna (MRNA) Halting Development of mRNA-1647 CMV Vaccine - Yahoo Finance
Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories - The Asheville Citizen Times
Moderna, Inc. (MRNA) Stock Forecasts - Yahoo Finance
UBS Adjusts Moderna (MRNA) Price Target to $40, Maintains Buy Ra - GuruFocus
Moderna’s cytomegalovirus vaccine fails a phase III - BioWorld MedTech
Moderna Flunks Pivotal CMV Trial, But Read-Through Unlikely - Citeline News & Insights
0.71%
1.60%
자본화:
|
볼륨(24시간):